Literature DB >> 15817280

Permeability of the blood-brain barrier to HIV-1 Tat.

William A Banks1, Sandra M Robinson, Avindra Nath.   

Abstract

Infection with human immunodeficiency virus-1 (HIV-1) is associated with dysfunctions of the central nervous system (CNS). HIV-1 induces its effects on the CNS by a variety of mechanisms, including by shedding the neurotoxic viral proteins such as gp120 and Tat. Both HIV-1 and gp120 have been shown to cross the blood-brain barrier (BBB). It is has not been determined, however, whether blood-borne Tat can cross the BBB. Here, we found that Tat crosses the BBB by a nonsaturable mechanism with a unidirectional influx rate of about 0.490 microl/g/min. About 0.126% of an intravenous dose of Tat enters each g of brain. Radioactively labeled albumin injected simultaneously did not cross the BBB. The hypothalamus, occipital cortex, and hippocampus were the regions of the brain most permeable to Tat. Nonsaturable brain-to-blood efflux also occurred, most likely with reabsorption into the blood of the cerebrospinal fluid. In conclusion, we found that Tat crossed the BBB bidirectionally. Such permeability could provide a mechanism by which Tat produced on one side of the BBB could affect neural or immune function on the other side.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15817280     DOI: 10.1016/j.expneurol.2004.11.019

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  77 in total

Review 1.  The role of medical imaging in defining CNS abnormalities associated with HIV-infection and opportunistic infections.

Authors:  David F Tate; Rola Khedraki; Daniel McCaffrey; Daniel Branson; Jeffrey Dewey
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

3.  Differential induction of rat neuronal excitotoxic cell death by human immunodeficiency virus type 1 clade B and C tat proteins.

Authors:  Grant R Campbell; Jennifer D Watkins; Erwann P Loret; Stephen A Spector
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-07       Impact factor: 2.205

4.  SMAD proteins of oligodendroglial cells regulate transcription of JC virus early and late genes coordinately with the Tat protein of human immunodeficiency virus type 1.

Authors:  Michelle R Stettner; Jonas A Nance; Clayton A Wright; Yayoi Kinoshita; Woong-Ki Kim; Susan Morgello; Jay Rappaport; Kamel Khalili; Jennifer Gordon; Edward M Johnson
Journal:  J Gen Virol       Date:  2009-05-06       Impact factor: 3.891

Review 5.  Defining the molecular mechanisms of HIV-1 Tat secretion: PtdIns(4,5)P2 at the epicenter.

Authors:  Anthony R Mele; Jamie Marino; Kenneth Chen; Vanessa Pirrone; Chris Janetopoulos; Brian Wigdahl; Zachary Klase; Michael R Nonnemacher
Journal:  Traffic       Date:  2018-04-30       Impact factor: 6.215

6.  Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma.

Authors:  Chuanyi Zheng; Chunyang Ma; Enqi Bai; Kun Yang; Ruxiang Xu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

7.  Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A Review.

Authors:  Bryan P Irish; Zafar K Khan; Pooja Jain; Michael R Nonnemacher; Vanessa Pirrone; Saifur Rahman; Nirmala Rajagopalan; Joyce B Suchitra; Kate Mostoller; Brian Wigdahl
Journal:  Am J Infect Dis       Date:  2009-07-01

Review 8.  Mouse models of neurological disorders: a view from the blood-brain barrier.

Authors:  William A Banks
Journal:  Biochim Biophys Acta       Date:  2009-10-29

9.  Cannabinoids inhibit migration of microglial-like cells to the HIV protein Tat.

Authors:  Daniel Fraga; Erinn S Raborn; Gabriela A Ferreira; Guy A Cabral
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-07       Impact factor: 4.147

10.  Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphorylation.

Authors:  Mahmoud L Soliman; Jonathan D Geiger; Xuesong Chen
Journal:  J Neuroimmune Pharmacol       Date:  2016-09-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.